Millions of people across the United States will sit down Nov. 27 to a traditional Thanksgiving meal, including turkey, potatoes, squash, corn and cranberries. These […]

The post Where did your favorite Thanksgiving Day food originate? Anthropology has the answer appeared first on Smithsonian Insider.

Giant pandas. Grizzlies. Polar bears. You’ve probably heard a lot about these bear species, but what about Andean bears? To the Quechua and Aymara, the […]

The post 6 Things You Probably Didn’t Know About Andean Bears appeared first on Smithsonian Insider.

Neanderthals (Homo neanderthalensis) were widespread across Europe and Western Asia for a long time, starting about 400,000 years ago. But things began to change when […]

The post Why did Neanderthals go extinct? appeared first on Smithsonian Insider.

Contrary to popular imagery, massive volcanic eruptions or an asteroid impact may not have been the cause of the world’s first mass extinction. Rather, some […]

The post Did mystery worms cause world’s first mass extinction? appeared first on Smithsonian Insider.

One of the primary features that distinguish hominids such as chimpanzees, gorillas and humans from the rest of the animal kingdom are uniquely dexterous hands. […]

The post Did ripening fruit help hominids develop complex hands? appeared first on Smithsonian Insider.

The blue whale, which uses baleen to filter its prey from ocean water and can reach lengths of over 100 feet, is the largest vertebrate […]

The post Only recently did whales become giant appeared first on Smithsonian Insider.

Looking for another Earth? An international team of researchers has pinpointed which of the more than 4,000 exoplanets discovered by NASA’s Kepler mission are most […]

The post Another Earth? Kepler astronomers pinpoint likeliest candidates appeared first on Smithsonian Insider.

This scientific visualization is much more than a dizzying dance of whirling worlds. It shows 2,299 planets found by NASA’s Kepler planet-hunting spacecraft.

The post Animation: Dizzying dance of the Kepler candidates appeared first on Smithsonian Insider.

Bocas Research Station’s research assistant Arcadio Castillo ran into these curious looking fish babies while working close to the dock. After some investigation, we found […]

The post Toadfish (Batrachoididae) babies in Bocas del Toro, Panama appeared first on Smithsonian Insider.

Just like humans, great apes can catch the flu. That’s why the Smithsonian’s National Zoo’s primate keepers train our gorillas and orangutans—like Iris, featured here—to […]

The post Get a flu shot? These orangutans did…. appeared first on Smithsonian Insider.

Why do we love orchids so much? Tom Mirenda, Smithsonian Gardens orchid collection specialist, believes it is partly because orchids seem to look back at […]

The post 5 Crazy Things You Didn’t Know About Orchids appeared first on Smithsonian Insider.

Source: Streetwise Reports   05/06/2020

In a May 4 research note, H.C. Wainwright & Co. analyst Ed Arce reported that Arcturus Therapeutics Holdings Inc. (ARCT:NASDAQ) formed a partnership with Catalent Inc. (CTLT:NYSE), which "raises the profile of LUNAR-COV19 as a leading vaccine candidate."

Arce reviewed Catalent's contribution to the partnership. The global contract development and manufacturing organization is to manufacture Arcturus' messenger RNA (mRNA) LUNAR-COV19 for protection against SARS-CoV-2 to be used first for human clinical trials and potentially, eventually commercially.

As for timing, Arce noted, San Diego, Calif.-based Arcturus intends to transfer its vaccine technology to Catalent this month and expects Catalent to manufacture the first batches of LUNAR-COV19 by June 2020. "Critically, Arcturus continues to anticipate initiation of Phase 1 testing of LUNAR-COV19 in the summer of 2020," Arce highlighted.

Catalent is to produce the vaccine at its biomanufacturing facility in Madison, Wisc. "This facility utilizes Catalent's flex-suite, a current good manufacturing practice manufacturing suite, that can produce batches at multiple scales and support Arcturus' proprietary mRNA manufacturing process," explained Arce.

Obtaining the vaccine from one facility domestically versus multiple entities worldwide should result in several benefits, Arce continued. They include easy development and production, accelerated delivery and improved costs. Arcturus believes Catalent can produce millions of doses of LUNAR-COV19 mRNA in 2020 and, if need be, hundreds of millions of doses each year subsequently for use globally.

Arce pointed out that LUNAR-COV19 differentiates itself from other similar vaccine candidates in that the technology and delivery platform behind it deliver an "extraordinarily low dose (perhaps 2 micrograms)" in "a potential single shot."

H.C. Wainwright has a Buy rating and a $62 per share price target on Arcturus, the stock of which is currently trading at about $42.12 per share.

Disclosure:
1) Doresa Banning compiled this article for Streetwise Reports LLC and provides services to Streetwise Reports as an independent contractor. She or members of her household own securities of the following companies mentioned in the article: None. She or members of her household are paid by the following companies mentioned in this article: None.
2) The following companies mentioned in this article are billboard sponsors of Streetwise Reports: None. Click here for important disclosures about sponsor fees.
3) Comments and opinions expressed are those of the specific experts and not of Streetwise Reports or its officers. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security.
4) The article does not constitute investment advice. Each reader is encouraged to consult with his or her individual financial professional and any action a reader takes as a result of information presented here is his or her own responsibility. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. This article is not a solicitation for investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company mentioned on Streetwise Reports.
5) From time to time, Streetwise Reports LLC and its directors, officers, employees or members of their families, as well as persons interviewed for articles and interviews on the site, may have a long or short position in securities mentioned. Directors, officers, employees or members of their immediate families are prohibited from making purchases and/or sales of those securities in the open market or otherwise from the time of the interview or the decision to write an article until three business days after the publication of the interview or article. The foregoing prohibition does not apply to articles that in substance only restate previously published company releases.
6) This article does not constitute medical advice. Officers, employees and contributors to Streetwise Reports are not licensed medical professionals. Readers should always contact their healthcare professionals for medical advice.

Disclosures from H.C. Wainwright & Co., Arcturus Therapeutics Holdings Inc., First Take, May 4, 2020

Investment Banking Services include, but are not limited to, acting as a manager/co-manager in the underwriting or placement of securities, acting as financial advisor, and/or providing corporate finance or capital markets-related services to a company or one of its affiliates or subsidiaries within the past 12 months.

I, Ed Arce, certify that 1) all of the views expressed in this report accurately reflect my personal views about any and all subject securities or issuers discussed; and 2) no part of my compensation was, is, or will be directly or indirectly related to the specific recommendation or views expressed in this research report; and 3) neither myself nor any members of my household is an officer, director or advisory board member of these companies.

None of the research analysts or the research analyst's household has a financial interest in the securities of Arcturus Therapeutics Holdings Inc. (including, without limitation, any option, right, warrant, future, long or short position).

As of April 30, 2020 neither the Firm nor its affiliates beneficially own 1% or more of any class of common equity securities of Arcturus Therapeutics Holdings Inc.

Neither the research analyst nor the Firm has any material conflict of interest in of which the research analyst knows or has reason to know at the time of publication of this research report.

The research analyst principally responsible for preparation of the report does not receive compensation that is based upon any specific investment banking services or transaction but is compensated based on factors including total revenue and profitability of the Firm, a substantial portion of which is derived from investment banking services.

The firm or its affiliates received compensation from Arcturus Therapeutics Holdings Inc. for non-investment banking services in the previous 12 months.

The Firm or its affiliates did receive compensation from Arcturus Therapeutics Holdings Inc. for investment banking services within twelve months before, and will seek compensation from the companies mentioned in this report for investment banking services within three months following publication of the research report.

H.C. Wainwright & Co., LLC managed or co-managed a public offering of securities for Arcturus Therapeutics Holdings Inc. during the past 12 months.

The Firm does not make a market in Arcturus Therapeutics Holdings Inc. as of the date of this research report.

H.C. Wainwright & Co., LLC and its affiliates, officers, directors, and employees, excluding its analysts, will from time to time have long or short positions in, act as principal in, and buy or sell, the securities or derivatives (including options and warrants) thereof of covered companies referred to in this research report.

( Companies Mentioned: ARCT:NASDAQ, )

4 awesome discoveries you probably didn't hear about this week -- Episode 31

4 awesome discoveries you probably didn't hear about this week -- Episode 32

4 awesome discoveries you probably didn't hear about this week -- Episode 32

…and why are they selling it to other security vendors and product testers?

The post Professional data leakage: How did that security vendor get my personal data? appeared first on WeLiveSecurity

Source: Streetwise Reports   05/06/2020

In a May 4 research note, H.C. Wainwright & Co. analyst Ed Arce reported that Arcturus Therapeutics Holdings Inc. (ARCT:NASDAQ) formed a partnership with Catalent Inc. (CTLT:NYSE), which "raises the profile of LUNAR-COV19 as a leading vaccine candidate."

Arce reviewed Catalent's contribution to the partnership. The global contract development and manufacturing organization is to manufacture Arcturus' messenger RNA (mRNA) LUNAR-COV19 for protection against SARS-CoV-2 to be used first for human clinical trials and potentially, eventually commercially.

As for timing, Arce noted, San Diego, Calif.-based Arcturus intends to transfer its vaccine technology to Catalent this month and expects Catalent to manufacture the first batches of LUNAR-COV19 by June 2020. "Critically, Arcturus continues to anticipate initiation of Phase 1 testing of LUNAR-COV19 in the summer of 2020," Arce highlighted.

Catalent is to produce the vaccine at its biomanufacturing facility in Madison, Wisc. "This facility utilizes Catalent's flex-suite, a current good manufacturing practice manufacturing suite, that can produce batches at multiple scales and support Arcturus' proprietary mRNA manufacturing process," explained Arce.

Obtaining the vaccine from one facility domestically versus multiple entities worldwide should result in several benefits, Arce continued. They include easy development and production, accelerated delivery and improved costs. Arcturus believes Catalent can produce millions of doses of LUNAR-COV19 mRNA in 2020 and, if need be, hundreds of millions of doses each year subsequently for use globally.

Arce pointed out that LUNAR-COV19 differentiates itself from other similar vaccine candidates in that the technology and delivery platform behind it deliver an "extraordinarily low dose (perhaps 2 micrograms)" in "a potential single shot."

H.C. Wainwright has a Buy rating and a $62 per share price target on Arcturus, the stock of which is currently trading at about $42.12 per share.

Disclosure:
1) Doresa Banning compiled this article for Streetwise Reports LLC and provides services to Streetwise Reports as an independent contractor. She or members of her household own securities of the following companies mentioned in the article: None. She or members of her household are paid by the following companies mentioned in this article: None.
2) The following companies mentioned in this article are billboard sponsors of Streetwise Reports: None. Click here for important disclosures about sponsor fees.
3) Comments and opinions expressed are those of the specific experts and not of Streetwise Reports or its officers. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security.
4) The article does not constitute investment advice. Each reader is encouraged to consult with his or her individual financial professional and any action a reader takes as a result of information presented here is his or her own responsibility. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. This article is not a solicitation for investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company mentioned on Streetwise Reports.
5) From time to time, Streetwise Reports LLC and its directors, officers, employees or members of their families, as well as persons interviewed for articles and interviews on the site, may have a long or short position in securities mentioned. Directors, officers, employees or members of their immediate families are prohibited from making purchases and/or sales of those securities in the open market or otherwise from the time of the interview or the decision to write an article until three business days after the publication of the interview or article. The foregoing prohibition does not apply to articles that in substance only restate previously published company releases.
6) This article does not constitute medical advice. Officers, employees and contributors to Streetwise Reports are not licensed medical professionals. Readers should always contact their healthcare professionals for medical advice.

Disclosures from H.C. Wainwright & Co., Arcturus Therapeutics Holdings Inc., First Take, May 4, 2020

Investment Banking Services include, but are not limited to, acting as a manager/co-manager in the underwriting or placement of securities, acting as financial advisor, and/or providing corporate finance or capital markets-related services to a company or one of its affiliates or subsidiaries within the past 12 months.

I, Ed Arce, certify that 1) all of the views expressed in this report accurately reflect my personal views about any and all subject securities or issuers discussed; and 2) no part of my compensation was, is, or will be directly or indirectly related to the specific recommendation or views expressed in this research report; and 3) neither myself nor any members of my household is an officer, director or advisory board member of these companies.

None of the research analysts or the research analyst's household has a financial interest in the securities of Arcturus Therapeutics Holdings Inc. (including, without limitation, any option, right, warrant, future, long or short position).

As of April 30, 2020 neither the Firm nor its affiliates beneficially own 1% or more of any class of common equity securities of Arcturus Therapeutics Holdings Inc.

Neither the research analyst nor the Firm has any material conflict of interest in of which the research analyst knows or has reason to know at the time of publication of this research report.

The research analyst principally responsible for preparation of the report does not receive compensation that is based upon any specific investment banking services or transaction but is compensated based on factors including total revenue and profitability of the Firm, a substantial portion of which is derived from investment banking services.

The firm or its affiliates received compensation from Arcturus Therapeutics Holdings Inc. for non-investment banking services in the previous 12 months.

The Firm or its affiliates did receive compensation from Arcturus Therapeutics Holdings Inc. for investment banking services within twelve months before, and will seek compensation from the companies mentioned in this report for investment banking services within three months following publication of the research report.

H.C. Wainwright & Co., LLC managed or co-managed a public offering of securities for Arcturus Therapeutics Holdings Inc. during the past 12 months.

The Firm does not make a market in Arcturus Therapeutics Holdings Inc. as of the date of this research report.

H.C. Wainwright & Co., LLC and its affiliates, officers, directors, and employees, excluding its analysts, will from time to time have long or short positions in, act as principal in, and buy or sell, the securities or derivatives (including options and warrants) thereof of covered companies referred to in this research report.

( Companies Mentioned: ARCT:NASDAQ, )

The mobility solution brings till to the consumer in the store and enables closure of the entire billing and payment process where consumers are.

The Earth's moon may be a present from Venus, which once had a moon and then lost it.

Is Denver's B-Cycle program nothing but a form of U.N. control of the city? The Mayoral Republican gubernatorial frontrunner thinks so.

What did Jesus' drink at his last meal? Experts speculate what the modern-day counterpart would be, and you can try this at home, too.

The ancient Romans saw 'Pluto's Gate' in what is now modern-day Pamukkale in Turkey as the entrance to the underworld. Now we know how it worked.

So-called "green" kitty litter may be a good idea for eco-conscious cat lovers, but it's a bad idea for nuclear waste storage.

We have the British to thank for animal crackers, but there's a lot more you should know about this tasty snack.

Company co-founder and namesake passed away, leaving 'for greener fields and wilder woods.'

Our food blogger steps into a Whole Foods for the first time in years and learns a few things she didn’t know.

The magnitude 8.6 earthquake that struck in the Indian Ocean off the western coast of Sumatra today resurrected fears of a repeat of the 2004 Indian Ocean earth

Two documentaries revisit the 2004 disaster and explore how science has advanced since then.

Scientists have uncovered the mystery of beak evolution.

Michael Pollan explains in a nutshell how the system went from working well to its current state.

Endurance athlete Ben Lecomte attempted to swim across the Pacific Ocean to bring attention to the state of our oceans.

Spanish endurance athlete Antonio de la Rosa is the first to cross the Pacific on a paddleboard.

NASA's first space shuttle, the test orbiter Enterprise, was named after the fictional starship on "Star Trek."

A new study suggests that dark matter from the galactic plane may have been what really killed the dinosaurs — and it may one day threaten us.

Phil Jones and The Union of Concerned Scientists say The Daily Mail misrepresented a statement about climate change data to support skeptics' claims.

Vijay Brihmadesam, one of the minds behind Tava Indian Kitchen, has mastered the tasty and convenient fast-food market.

The Environmental Voter Project has a plan to awaken a sleeping giant in American politics.

Drug-resistant and sometimes fatal fungus Candida auris has been found in the U.S., and it's hard to detect.

It has to do with civic involvement and not an issue with nature.

The extremely rare South Pacific island is one of three new islands to form in the last 150 years.

Bring the great outdoors into your home with Three Bad Seeds' line of wilderness-inspired pillows handcrafted from repurposed scrap fabrics.

People living in the the U.S. and the E.U. are responsible for the greatest average loss of Arctic sea ice, says Max Planck Institute.

Now all Republican Senate candidates this November are on the record denying global warming.

Drilling in the Arctic National Wildlife Refuge was one of the few mentions of energy policy during the latest Alaska U.S. Senate Debate.

In honor of American Made Matters Day, we rounded up 10 products manufactured in the U.S.

Epicurious picks the 100 greatest home cooks of all time, and you might be surprised by the names on the list.

These small horses were thought to be the only truly wild horse species left on the planet and have a fascinating history.

He may be one of the most famous men who ever lived, but there's plenty to learn about Nelson Mandela.

Beyond their undeniable cuteness, there's a lot more to discover about these wonderfully odd creatures.

There's more to an alpaca than their quirky good looks. Did you know the fiber from their fleece is flame-resistant? Here are 11 alpaca facts you may not know.